Clinical trials: Anti-Retroviral Agents
Medication Adherence
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)
This is a pilot study to assess the feasibility, acceptability and appropriateness of delivery of the investigational "MedViewer" intervention in adult patients living with HIV who have been prescribed antiretroviral (ARV)…
- Trial name
- ENLIGHTEN (NCT04232540)
- Testing
- MedViewer report
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV, AIDS
Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru
Using quantitative and qualitative data, this study will assess the impact of community accompaniment with supervised antiretrovirals (CASA) on HIV-positive individuals and community members in Lima, Peru.
- Conditions
- HIV, AIDS, HIV Infections
- Trial name
- CASA (NCT01070017)
- Testing
- DOT-HAART
- Where
- Peru
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Cryptococcal Meningitis, HIV Infections
Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis
The goal of this randomized clinical trial is to compare early versus standard timing of initiation of antiretroviral therapy (ART) with respect to clearance of Cryptococcus neoformans from cerebrospinal fluid (CSF) among…
- Trial name
- Crypto (NCT00976040)
- Testing
- Early antiretroviral therapy
- Where
- Botswana
- Volunteers
- 28 people
- Sponsor
- Botswana-UPenn Partnership
Cryptococcal Meningitis, HIV Infections
Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
Cryptococcal Meningitis continues to be one of the most devastating AIDS defining illness in sub-Saharan Africa. Despite the availability of azoles such as fluconazole for treatment, mortality remains high with some studies…
- Trial name
- NCT00830856
- Testing
- Fluconazole, Fixed dose - Stavudine, lamivudine and Nevirapine, Fixed dose - Stavudine, Lamivudine, Nevirapine
- Where
- Zimbabwe
- Volunteers
- 54 people
- Sponsor
- University of Zimbabwe
HIV Infections
The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens
In this study the researchers will be enrolling patients who are failing their current antiretroviral regimen who also have resistance to 3TC or FTC.
- Trial name
- NCT00152061
- Testing
- 3TC and FTC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Chronic HIV Infection
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
- Trial name
- NCT06006546
- Testing
- 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.
This 2 arm study will assess the immunological benefits of adding Fuzeon to an antiretroviral regimen in HIV-infected, Fuzeon-naive patients with a CD4 cell count <250 cells/mm3 and an HIV RNA viral load <400 copies/mL.
- Trial name
- NCT00461266
- Testing
- enfuvirtide [Fuzeon], Antiretroviral therapy
- Where
- 7 sites in Australia
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus (HIV), Tuberculosis
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
Tenofovir (TFV) disoproxil fumarate (TDF) plus emtricitabine (FTC) or lamivudine (3TC) is the preferred nucleoside backbone of first-line antiretroviral therapy (ART) for adolescents in sub-Saharan Africa.
- Conditions
- Human Immunodeficiency Virus (HIV), Tuberculosis, Coinfection
- Trial name
- NCT03800394
- Testing
- Observational PK study
- Where
- Ghana
- Volunteers
- 52 people
- Sponsor
- University of Florida
HIV
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
The purpose of this study is to evaluate the safety and tolerability of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.
- Trial name
- NCT02390466
- Testing
- VAC-3S
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- InnaVirVax
HIV Infections
BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to…
- Trial name
- NCT00388492
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Bellos, Nicholaos C., M.D.
HIV/HCV Co-infection, HIV Infections
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
The aim of this study is to assess the efficacy of lopinavir/r in monotherapy and peg-interferon plus ribavirin for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV.
- Trial name
- PEKARI (NCT00866021)
- Testing
- Lopinavir/ritonavir, Lopinavir/ritonavir with two nucleoside analogs
- Where
- 10 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundacion SEIMC-GESIDA
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16…
- Trial name
- NCT00000907
- Where
- 24 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
To test the hypothesis that AGT103-T cells therapy will allow HIV positive individual to reduce, modify or eliminate antiretroviral therapy.
- Trial name
- NCT05540964
- Testing
- Antiretroviral Therapy Interruption(ATI)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
Human Immunodeficiency Virus
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and…
- Trial name
- UW PIC 330 (NCT00781287)
- Testing
- 3-drug anti-HIV therapy, Raltegravir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
HIV Infections
IL-7 Receptor Polymorphisms and Immune Recovery With HAART
The aim is to investigate the hypothesis that IL7-receptor polymorphisms contribute to the differential immune recovery of CD4 + T cells following HAART
- Trial name
- NCT00168207
- Where
- Australia
- Volunteers
- 106 people
- Sponsor
- The Alfred
Hiv, HBV Coinfection
Towards a Functional Cure for HBV - The COMMIT Cohort Study
Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint.
- Trial name
- COMMIT (NCT03645044)
- Where
- 3 sites in India, Malaysia and 1 more
- Volunteers
- 102 people
- Sponsor
- University of Melbourne
HIV, Antiretroviral Therapy
Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-Malawi
In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization (WHO) called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for…
- Trial name
- SPRINT-Malawi (NCT04468399)
- Testing
- Routine medical record data collection, Interviews with service providers
- Where
- 2 sites in Malawi, South Africa
- Volunteers
- 1,781 people
- Sponsor
- Boston University
HIV Infections
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
Long-term control of HIV depends on improvement in an individual's immune system. The purpose of this study is to see if either stopping anti-HIV drugs for short periods of time and/or adding a vaccine to the anti-HIV drugs being…
- Trial name
- NCT00011011
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 16 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Chronic immune activation is a central feature of HIV-infection, and the degree of activated T-cells is a better predictor of disease progression and mortality than plasma viral load.
- Trial name
- OUSCOX2 (NCT01269515)
- Testing
- Etoricoxib
- Where
- 2 sites in Norway
- Volunteers
- 60 people
- Sponsor
- Dag Kvale
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.